azilsartan medoxomil + hydrochlorothiazide

Azilsartan medoxomil + hydrochlorothiazide is an oral antihypertensive co-administration regimen comprising azilsartan medoxomil, a prodrug converted to the selective angiotensin II type 1 receptor antagonist azilsartan, and hydrochlorothiazide, a thiazide diuretic. Azilsartan reduces angiotensin II-mediated vasoconstriction and aldosterone signaling, while hydrochlorothiazide inhibits renal sodium-chloride reabsorption in the distal convoluted tubule, promoting natriuresis and lowering blood pressure. This exact two-drug regimen was evaluated by Takeda in a Phase 3 study in moderate-to-severe essential hypertension; it is distinct from Edarbyclor, which contains azilsartan medoxomil + chlorthalidone rather than hydrochlorothiazide. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT00818883))

Other names

azilsartan medoxomil + HCTZazilsartan medoxomil/hydrochlorothiazideTAK-491 + hydrochlorothiazide